Texas has tapped Nobel-Prize winning biochemist Alfred Gilman to serve as chief scientific officer of its new cancer research institute, which could receive up to $3 billion from bonds over 10 years for cancer research.
That sum is comparable to the size of California's stem cell research initiative. Gilman will step down from his post as executive vice president for academic affairs and provost of the University of Texas Southwestern Medical Center to join the Cancer Prevention and Research Institute of Texas, which was created by the Texas legislature in 2007. One of his duties there will be to set up a peer review process for grant applications. But he won't leave his positions on the boards of two drug companies.